Fat Loss Protocol

Overview

Peptide-based fat loss protocols target multiple physiological pathways involved in lipid metabolism, appetite regulation, and body composition. Unlike stimulant-based fat burners, these peptides work through hormonal signaling — stimulating lipolysis (fat breakdown), modulating appetite, or enhancing growth hormone's fat-metabolizing effects.

Three primary categories of peptides are used in fat loss protocols:

1. GH fragment peptides (AOD-9604) — target the lipolytic portion of the growth hormone molecule
2. GHRH analogs (Tesamorelin) — stimulate endogenous GH release with downstream fat-metabolizing effects
3. GLP-1 receptor agonists (Semaglutide, Tirzepatide) — regulate appetite and glucose metabolism through incretin pathways

These compounds are often used individually or in combination, depending on the specific goals and context of the research protocol.

Compounds Involved

AOD-9604

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) with an added tyrosine residue. It was designed to isolate the fat-metabolizing properties of GH without the growth-promoting or glucose-affecting effects. Research suggests it stimulates lipolysis and inhibits lipogenesis (new fat formation) without affecting blood sugar or IGF-1 levels.

Tesamorelin

Tesamorelin is a GHRH analog that has been studied extensively for the reduction of visceral adipose tissue. It stimulates the pituitary to release growth hormone, which then promotes lipolysis through downstream signaling. Unlike direct GH administration, Tesamorelin preserves the pulsatile nature of GH release.

GLP-1 Receptor Agonists

GLP-1 (glucagon-like peptide-1) receptor agonists mimic the incretin hormone GLP-1, which is released from the gut after eating. These compounds reduce appetite by slowing gastric emptying and acting on central appetite-regulating centers in the hypothalamus. They also improve insulin sensitivity and glucose metabolism.

Protocol Structure

AOD-9604 Protocol (Weeks 1–12)

Dosing:

• 250–500 mcg per day, split into 1–2 injections
• Subcutaneous injection, abdominal area preferred

Timing:

• Administer on an empty stomach (fasted state)
• Morning administration before fasted cardio is the most common approach
• If splitting doses: morning (fasted) and pre-bed
• No food for 30 minutes after injection

Protocol duration: 8–12 weeks, followed by a 4-week break

Tesamorelin Protocol (Weeks 1–12)

Dosing:

• 1–2 mg per day, single injection
• Subcutaneous injection, abdominal area

Timing:

• Administer before bed on an empty stomach
• The pre-bed timing leverages the natural nocturnal GH pulse
• No food for 2 hours before injection

Protocol duration: 12–26 weeks (Tesamorelin has been studied in longer protocols than most peptides)

GLP-1 Agonist Protocol

GLP-1 agonists follow a gradual dose escalation to minimize gastrointestinal side effects:

Semaglutide titration schedule:

Administration: Subcutaneous injection, any site (abdomen, thigh, upper arm). GLP-1 agonists do not require fasted administration.

Fasted Cardio Timing

Fasted cardio is commonly paired with AOD-9604 and Tesamorelin to maximize lipolytic activity:

Suggested morning routine:

1. Wake, administer AOD-9604 (fasted)
2. Wait 15–20 minutes
3. Perform 30–45 minutes of low-to-moderate intensity cardio (walking, cycling, elliptical)
4. Wait an additional 15–30 minutes before eating

The rationale is that fasted exercise in the presence of lipolytic peptides creates optimal conditions for fat oxidation — insulin is low, catecholamines are elevated, and the peptide-driven lipolytic signal is active.

Combination Approaches

Some protocols combine multiple fat loss peptides for complementary effects:

AOD-9604 + Tesamorelin:

• AOD-9604 in the morning (fasted, pre-cardio)
• Tesamorelin at night (pre-bed)
• Duration: 12 weeks

AOD-9604 + GLP-1 agonist:

• AOD-9604 daily (fasted morning)
• Semaglutide or Tirzepatide weekly
• Duration: 12–16 weeks

Secretagogue stack for fat loss:

• Ipamorelin + Mod GRF 1-29 (see GH Secretagogue Protocol)
• This approach uses endogenous GH elevation rather than GH fragments

Important Considerations

• Diet remains foundational: No peptide protocol replaces a caloric deficit for fat loss. These compounds are studied as adjuncts to proper nutrition and exercise programming.
• GLP-1 side effects: Nausea, reduced appetite, and gastrointestinal discomfort are common during the titration phase of GLP-1 agonists. Slow dose escalation helps mitigate these effects.
• Muscle preservation: AOD-9604 and Tesamorelin do not appear to significantly affect lean mass. GLP-1 agonists may contribute to lean mass loss during aggressive weight loss — adequate protein intake (1.6–2.2 g/kg) and resistance training are recommended to counter this.
• Blood glucose monitoring: Both Tesamorelin (through GH elevation) and GLP-1 agonists (through insulin modulation) can affect glucose metabolism. Regular monitoring is prudent.
• Cycling AOD-9604: Extended use beyond 12 weeks without a break is not well studied. Standard practice includes off periods. See Peptide Cycling.
• GLP-1 discontinuation: Appetite typically returns to baseline after discontinuing GLP-1 agonists. Gradual tapering and established dietary habits help with transition.
• Hydration: Increased lipolysis and reduced food intake both increase the importance of adequate hydration throughout these protocols.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.